Could Hepcidin Be a Phenotype-Related Biomarker in Patients with Stable Bronchiectasis?
Open Access
Abstract
Hepcidin centrally regulates iron homeostasis and responds to inflammation, iron status, hypoxia, and erythropoietic signaling, yet circulating hepcidin in stable bronchiectasis is poorly characterized. We compared serum hepcidin between 61 patients with stable bronchiectasis and 39 controls without bronchiectasis and assessed associations with anemia, iron metabolism, systemic inflammation, severity, and phenotype. Hepcidin was lower in bronchiectasis (20.34 ± 7.85 vs. 28.34 ± 9.82 ng/mL; median, 20.31 [15.07–25.35] vs. 25.03 [21.00–34.66] ng/mL; p < 0.001). It showed no significant associations with anemia status or hematologic, iron metabolism, erythropoietic, or inflammatory indices. Exploratory analyses identified phenotype differences (p = 0.002); levels were lowest in chronic obstructive pulmonary disease–bronchiectasis (15.98 ± 6.52 ng/mL), compared with bronchiectasis alone (21.57 ± 6.71) and asthma–bronchiectasis (24.81 ± 9.00). Low hepcidin discriminated bronchiectasis from controls (AUC = 0.729; 95% bootstrap CI: 0.628–0.822); the ≤20.85 ng/mL cutoff yielded 59.0% sensitivity and 79.5% specificity. To our knowledge, this is the first human case–control evidence of reduced circulating hepcidin in stable bronchiectasis. The absence of significant associations with systemic inflammation or anemia/iron status, alongside phenotype differences, suggests that hepcidin may be a candidate biomarker of biological heterogeneity in bronchiectasis not reflected by routine markers.Keywords
This publication has 57 references indexed in Scilit:
- Hepcidin Isoforms in Chronic Obstructive Pulmonary Disease Compared with the General PopulationThe Journal of Applied Laboratory Medicine, 2025
- Baseline neutrophil-to-lymphocyte ratio as a predictor of response to hospitalized bronchiectasis exacerbation risksEuropean Clinical Respiratory Journal, 2024
- Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort StudyLung, 2024
- Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasisRespiratory Medicine, 2021
- C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)Archivos de Bronconeumología, 2021
- Hepcidin as a new biomarker for detecting autologous blood transfusionAmerican Journal of Hematology, 2016
- Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary diseaseClinical Biochemistry, 2015
- Hepcidin--a well-known iron biomarker with prognostic implications in chronic kidney diseaseNephrology Dialysis Transplantation, 2013
- Serum hepcidin and prohepcidin concentrations in inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 2011
- Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the LiverJournal of Biological Chemistry, 2001